FDA’s AEMS pages include a public dashboard and a standing page for new safety information or potential signals of serious risks. FDA also maintains a 2026 Safety and Availability Communications page for biologics and a long-running Drug Safety Communications hub. The agency says these pages are intended to provide the public with important information about product safety and availability.
Inference: taken together, these pages suggest regulators are building more always-on, category-specific, public-facing safety infrastructure rather than relying only on isolated announcements. That shift matters because it changes how companies, clinicians, journalists, and patients encounter safety information over time.
For pharmacovigilance teams, the practical implication is that external safety intelligence is becoming more continuous, easier to monitor, and potentially more visible to wider audiences than before.
0 Comments